Trials / Completed
CompletedNCT00633048
Study Evaluating the Safety and Tolerability of NSA-789
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NSA-789 | |
| DRUG | placebo |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-03-11
- Last updated
- 2009-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00633048. Inclusion in this directory is not an endorsement.